David Moreira Appointed Vice President of Marketing, Menicon A... - 20 July 2010 15:00

NAGOYA, Japan, July 20 /Kyodo JBN-AsiaNet/-- -Menicon focusing on expanding its presence in the custom contact lens market- Menicon Co., Ltd. announced on July 20 the appointment of David Moreira as Vice President of Marketing for Menicon America Inc. Moreira will report to Jonathan Jacob...

  Innovative Partnership Helps Improve Medical Research by Optim... - 20 July 2010 08:00

NEW YORK, July 20 /PRNewswire-AsiaNet/ -- Target Health Inc. and LifeOnKey, Inc. Team Up to Bring State-Of-The-Art Information Technology System to Clinical Trial Process Target Health Inc. and LifeOnKey, Inc. today announced they have joined forces to offer an i...

  Aegera Therapeutics Reports Survival Data from the Phase 1 Por... - 20 July 2010 01:12

MONTREAL, Quebec, Canada and HONG KONG, China, July 19 /CNW-AsiaNet/ -- Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcin...

  Bill Gates: World Has Historic Opportunity to 'Change the Face... - 19 July 2010 21:21

VIENNA, July 19 /PRNewswire-AsiaNet/ -- In Keynote Speech to AIDS Conference, Gates Outlines Roadmap to Reduce Annual New HIV Infections 90% by 2031 Speaking to the 18th International AIDS Conference today, Bill Gates called on all countries to keep u...

  World's Largest Study on Insulin Therapy Completes Recruitment... - 19 July 2010 16:00

ZURICH, Switzerland, July 19 /PRNewswire-AsiaNet/ -- Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.[1] Spanning...

  Nitto Denko and Quark Pharmaceuticals to Enter Into Collaborat... - 15 July 2010 22:30

OSAKA, Japan and FREMONT, Calif., July 15 /PRNewswire-AsiaNet/ -- Nitto Denko to use its specialty delivery vehicle, targeting technology for fibrosis with novel therapeutic concepts together with Quark proprietary RNAi technology, novel structures with FTO and siRNA clinical developme...

  R-Tech Ueno Completes Phase II Clinical Study on Ophthalmic So... - 15 July 2010 19:05

TOKYO, July 15 /Kyodo JBN-AsiaNet/-- R-Tech Ueno, Ltd. announced on July 15 the completion of the Phase II clinical study on the ophthalmic solution UF-021 (product name Ocuseva (TM)) under development as a therapeutic drug for retinitis pigmentosa (Note 1). Below is a summary of the...

  Takeda Responds to FDA Advisory Committee Recommendation - 15 July 2010 09:31

DEERFIELD, Ill., July 15 /PRNewswire-AsiaNet/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular (CV) safety of ...

  New Research Advances from the Alzheimer's Association Interna... - 15 July 2010 03:30

HONOLULU, July 15 /PRNewswire-AsiaNet/ -- This week, nearly 4,000 scientists from around the world gathered to report and discuss the latest advances in research on treatments, risk factors, and diagnosis for the health epidemic of the 21st century - Alzheimer's disease - at the Al...

  Former Pfizer Senior Vice President Named CEO of Berlin Pharma... - 14 July 2010 14:20

BANGKOK, Thailand, July 14 /InfoQuest-AsiaNet/ -- Berlin Pharmaceutical Industry Co., Ltd., Thailand's leading manufacturer and marketer of generic pharmaceuticals, named Amal Naj, a former Senior Vice President of New York-based Pfizer Inc., Chief ExecutiveOfficer and a member of the Board. I...